“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s49. Accessed April 20, 2026. https://skin.dermsquared.com/skin/article/view/1804.